On September 17, 2026, seven life sciences companies will present live at the Life Sciences Virtual Investor Forum, a B2i Digital Featured Conference hosted by Virtual Investor Conferences. The event, held online, offers investors a direct line to executive management teams through 30-minute presentations followed by audience Q&A. Replays will be available on demand via the B2i Digital and OTC Markets YouTube channels. Registration is open at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC.
The forum matters because it assembles a diverse slate of emerging biotech and medtech companies, each targeting areas of significant unmet need. Sona Nanotech Inc. will present a photothermal cancer therapy built on gold nanorods, a platform that could offer a less invasive approach to solid tumors. Raphael Pharmaceutical brings cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease, reflecting the growing interest in cannabinoid therapeutics beyond pain management. Amplia Therapeutics Ltd. will discuss its pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, a mechanism that addresses both tumor progression and fibrotic tissue formation. Adaptin Bio, Inc. focuses on precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier, a persistent challenge in treating neurological conditions. Acurx Pharmaceuticals, Inc. is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens, a critical need amid rising antimicrobial resistance. CytoDyn Inc. will present a humanized monoclonal antibody being studied in solid-tumor oncology, adding to the immuno-oncology landscape. 4DMedical Ltd. offers FDA-cleared four-dimensional respiratory imaging, a diagnostic tool that could improve how lung diseases are detected and monitored.
David Shapiro, Chief Executive Officer of B2i Digital, Inc., emphasized the value of live interaction: “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” The format allows investors to probe management on strategy, data, and timelines in real time, rather than relying solely on static disclosures.
B2i Digital is the Official Marketing Partner, leveraging a media network of over 800 outlets, a combined monthly audience exceeding 330 million, and a community of more than 1.7 million followers. The event is part of Virtual Investor Conferences’ ongoing series that connects public companies from global exchanges, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets, with investors online. Virtual Investor Conferences is an OTC Markets Group Inc. property. Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum.
The forum’s implications extend beyond a single day of presentations. For investors, it provides a rare opportunity to compare companies across multiple high-growth sectors in one sitting, potentially uncovering early-stage opportunities before they reach broader markets. For the companies, the exposure to a large investor audience can enhance visibility, liquidity, and access to capital. As drug development costs continue to rise and approval pathways grow more complex, platforms like this that facilitate direct dialogue between management and investors may become increasingly vital for capital formation in the life sciences.
